Abstract
The pharmaceutical industry is interested in developing new treatments for severe asthma (SA), recognising that there is a substantial unmet clinical need in this area. However, it faces a significant set of barriers in attempting to do so, including a) problems arising from the way SA is defined, b) the heterogeneity of this condition, c) poor understanding of its aetiology, d) the absence of validated animal and tissue or cellular models, e) the need for biomarkers and experimental clinical models of severe asthma and its sub-groups, and f) the length and size of the clinical trials likely to be required to obtain approval and reimbursement. The discovery and validation of novel biomarkers and surrogates is likely to be a crucial part of meeting these challenges, and many academic groups and pharmaceutical companies working in this area are increasingly turning to pre-competitive, highly collaborative ways of working to address them.
Keywords: Refractory asthma, difficult asthma, segmentation, phenotypes, biomarkers, collaboration, symptomatic, moderate asthma, budesonide, therapeutics, Severe asthma, hypothesised, aetiology, sputum eosinophil, epigenetic, biological flui, prednisolone, Diseases Symposium, Cohort Studies
Current Pharmaceutical Design
Title: Challenges for the Development of New Treatments for Severe Asthma: A Pharmaceutical Perspective
Volume: 17 Issue: 7
Author(s): Richard G. Knowles
Affiliation:
Keywords: Refractory asthma, difficult asthma, segmentation, phenotypes, biomarkers, collaboration, symptomatic, moderate asthma, budesonide, therapeutics, Severe asthma, hypothesised, aetiology, sputum eosinophil, epigenetic, biological flui, prednisolone, Diseases Symposium, Cohort Studies
Abstract: The pharmaceutical industry is interested in developing new treatments for severe asthma (SA), recognising that there is a substantial unmet clinical need in this area. However, it faces a significant set of barriers in attempting to do so, including a) problems arising from the way SA is defined, b) the heterogeneity of this condition, c) poor understanding of its aetiology, d) the absence of validated animal and tissue or cellular models, e) the need for biomarkers and experimental clinical models of severe asthma and its sub-groups, and f) the length and size of the clinical trials likely to be required to obtain approval and reimbursement. The discovery and validation of novel biomarkers and surrogates is likely to be a crucial part of meeting these challenges, and many academic groups and pharmaceutical companies working in this area are increasingly turning to pre-competitive, highly collaborative ways of working to address them.
Export Options
About this article
Cite this article as:
G. Knowles Richard, Challenges for the Development of New Treatments for Severe Asthma: A Pharmaceutical Perspective, Current Pharmaceutical Design 2011; 17 (7) . https://dx.doi.org/10.2174/138161211795429019
DOI https://dx.doi.org/10.2174/138161211795429019 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hydroxamic Acids as Pharmacological Agents
Current Medicinal Chemistry Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease
Current Pharmaceutical Design Severe Preeclampsia
Current Women`s Health Reviews COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Eotaxins and CCR3 Receptor in Inflammatory and Allergic Skin Diseases: Therapeutical Implications
Current Drug Targets - Inflammation & Allergy Dietary Interventions in Asthma
Current Pharmaceutical Design Chemical and Pharmacological Significance of Natural Guanidines from Marine Invertebrates
Mini-Reviews in Medicinal Chemistry Current Prospective of Anti-IL-4, -IL-9, and -IL-13 Therapies in Allergic Disease
Recent Patents on Inflammation & Allergy Drug Discovery Pharmacotherapy & Surgical Interventions Available for Obesity Management and Importance of Pancreatic Lipase Inhibitory Phytomolecules as Safer Anti-Obesity Therapeutics
Mini-Reviews in Medicinal Chemistry From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Effector Cells and Downstream Mediators in Severe Cutaneous Adverse Reactions
Current Immunology Reviews (Discontinued) Proteomic Insights into Inflammatory Airway Diseases
Current Proteomics Life Threatening and Fatal Contrast Media Reactions: Pathomechanisms, Diagnosis, Prevention and Drug Management
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Development and Clinical use of Prasugrel and Ticagrelor
Current Pharmaceutical Design Synthesis and Evaluation of Thiazolidinedione-Coumarin Adducts as Antidiabetic, Anti-Inflammatory and Antioxidant Agents
Letters in Organic Chemistry Editorial [Hot topic: Novel Approaches to Pharmacogenomic Investigations (Executive Editor: Kelan G. Tantisira)]
Current Pharmaceutical Design Vitamin D Deficiency and Acute Lung Injury
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacogenetics and the Pharmaceutical Industry
Current Pharmaceutical Design The Optimal Treatment of Severe Hypertension in Pregnancy: Update of the Role of Nicardipine
Current Pharmaceutical Biotechnology